Simcere Pharmaceutical Group Limited (HK:2096) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Simcere Pharmaceutical Group Limited has announced the signing of an exclusive agreement with TargetRx to commercialize a new non-small cell lung cancer drug, TGRX-326, in mainland China. The deal includes an initial payment of over $20 million to TargetRx, which will also receive compensation for promotional services. TGRX-326, a promising treatment for ALK/ROS1 positive fusion gene-driven cancer, has shown notable efficacy and safety in early trials and has the potential to treat brain metastases due to its high blood-brain barrier permeability.
For further insights into HK:2096 stock, check out TipRanks’ Stock Analysis page.